EyePoint prices public offering at $12.00 per share, raises $150M to boost DURAVYU™ Phase 3 clinical programs

EyePoint Pharmaceuticals (NASDAQ:EYPT [https://seekingalpha.com/symbol/EYPT]) has announced the pricing [https://seekingalpha.com/pr/20266005-eyepoint-announces-pricing-of-public-offering] of an underwritten public offering expected to generate approximately $150 million in gross proceeds. The capital raise is primarily aimed at accelerating the clinical development of the company's lead product candidate, DURAVYU™.

The offering consists of 11M shares of common stock priced at $12.00 per share. Additionally, the company is offering pre-funded warrants to certain investors, covering up to an aggregate of 1.5M shares of common stock.

The pre-funded warrants are priced at $11.999 each, reflecting the public offering price less a nominal exercise price of $0.001 per warrant.

All shares and warrants are being sold directly by EyePoint.

The closing of the offering is anticipated to occur on or about October 16, 2025.

The company has also granted the underwriters a 30-day option to purchase up to an additional 1,875,000 shares of common stock to cover any overallotment.

The company intends to allocate the capital proceeds to finance the advancement of DURAVYU™ in wet AMD and DME clinical development, bolster earlier pipeline initiatives, and cover general corporate expenses.

EYPT stock were down 5% after-hours on Tuesday.

MORE ON EYEPOINT PHARMACEUTICALS

* EyePoint Pharmaceuticals, Inc. (EYPT) Presents At Citi's Biopharma Back To School Conference Transcript [https://seekingalpha.com/article/4818690-eyepoint-pharmaceuticals-inc-eypt-presents-at-citis-biopharma-back-to-school-conference]
* EyePoint Pharmaceuticals, Inc. (EYPT) Q2 2025 Earnings Call Transcript [https://seekingalpha.com/article/4809732-eyepoint-pharmaceuticals-inc-eypt-q2-2025-earnings-call-transcript]
* EyePoint announces proposed public offering of common stock [https://seekingalpha.com/news/4504081-eyepoint-announces-proposed-public-offering-of-common-stock]
* EyePoint signals 2026 LUGANO Phase III data and NDA filing for DURAVYU amid accelerated trial enrollment [https://seekingalpha.com/news/4480395-eyepoint-signals-2026-lugano-phase-iii-data-and-nda-filing-for-duravyu-amid-accelerated-trial]
* Seeking Alpha’s Quant Rating on EyePoint Pharmaceuticals [https://seekingalpha.com/symbol/EYPT/ratings/quant-ratings]